publication venue for
- Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients. 829-836. 2023
- Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients. . 1-8. 2022
- Comment on: Reclassification into very-high cardiovascular risk in psoriatic arthritis as well as axial spondyloarthritis. 2020
- Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients? 2020
- Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. . 112-119. 2020
- Tocilizumab in giant cell arteritis_ differences between the GIACTA trial and a multicentre series of patients from clinical practice. 112-119. 2020
- Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis.. 145-148. 2017
- Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study 2016
- Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. 1-4. 2016
- Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. 1-2. 2014